EDITORIAL

Assessment of Altered Immune Status Induced by Immunomodulatory Drugs via an Apical Test in Mice
The immune system is a highly complex network composed of interrelated and often redundant pathways and signals. Assessment of a drug's potential to induce toxicologically relevant changes in this network must be made with a consideration of this complexity.
Assays that measure spleen weight and complete blood counts play a valuable role in screening for immunotoxicity. Other established and emerging in vitro and ex vivo immunotoxicology assays, such as the Jerne plaque assay and RT-PCR for cytokine gene expression, allow us to peer into the immune network to identify specific alterations that may be the basis of a perturbation in immune function. Despite these advances, it is only in an in vivo setting that we can assess how a therapeutic agent impacts the immune system in a way that allows the toxicologic pathologist to assess a potential risk to the host. As such, one significant assessment of immune system perturbation is to measure the ability of this system to protect the host from challenge by infectious agents found naturally in the environment.
In this issue of Toxicologic Pathology, Herzyk et al present a novel way of identifying the hazard and assessing the potential risk of an immunomodulatory drug to the immune system (1) . Although there are many other in vivo systems available, the approach they describe is unique in that it uses a single test organism in a single test strain of mice following a 14-day dosing regimen to test the effect of an immunomodulatory drug on all 3 immune effector systems (i.e., nonspecific, cell-mediated, and humoral immunity). In contrast to many of the established systems that rely on evaluating surrogate markers of immune function (e.g., the humoral response to a purified protein antigen administered with Freund's adjuvant), the models proposed by Herzyk et al measure immune responses in the setting of a whole process (i.e., agent and organism) through a single system. Moreover, in contrast to more established assays that evaluate parameters whose relevance in risk assessment is uncertain (e.g., a reduction in splenic plaque-forming cells), Herzyk et al advocate evaluating fundamental outcomes of host defense, such as host survival. Consequently, the approach they propose can evaluate immune function in the intact animal and give insight into the importance of drug-associated immune alteration to the host's health and well-being.
There is extensive laboratory data available for various immunologic parameters in animals and humans, but these values are generally for specific components of the immune system. Few measurements take into consideration the complete response of an intact, functioning sys-tem. The toxicologic pathologist must be able to look at the total milieu in which these reactions develop in order to assess them properly. Ex vivo assays used to assess immunocompetence define the defect and characterize the hazard, but additional studies must be undertaken to ascertain the relevance of these observations to the host.
Furthermore, host defense models are available to study the effect of xenobiotics on humoral or cellular immunity. However, in the Herzyk model of host defense, in which a single pathogen is used and multiple endpoints measuring different effector systems evaluated, some differential assessment of immune functions is possible in addition to the histological evaluation of target tissues and general measures of survival. Consequently, for compounds with known mechanisms of immunomodulatory activity, measurement of host resistance to organisms found normally in the environment can serve as an apical test.
By design, immunomodulatory drugs will modify immune function, thereby inducing changes in many assays designed to evaluate the immune system. The pharmacologic basis of activity is frequently well established for immunomodulatory drugs; risk assessment for these compounds generally relates more to how such a drug might perturb immune system homeostasis and host resistance and less to the specific alterations induced by the drug. A widely accepted approach for evaluating effects on host defense is to use a variety of organisms matched with different sensitive species for which different effector systems are considered to play an important role. Included among these approaches are streptococcal models that have been used to study the effects on the antibody-mediated immune system and Listeria monocytogenes and other microbes that have been used to assess delayed hypersensitivity reactions. Due to experimental differences in test organisms, the time course of infection, and the animal host being tested, a cross-experiment interpretation of the data is difficult. By using a single organism, standardizing the routes of inoculation, and configuring parameters used to evaluate the contribution of the different effector arms, Herzyk et al propose that they can avoid pitfalls of interexperiment extrapolation. Ad- ' ditional benefits of their model are that morphological assessments can be conducted within the known incidence of background alterations and spontaneous lesions of the mouse strain chosen while simultaneously assess-. ing immune function.
. The toxicologic pathologist is frequently confronted . with morphological changes that must be interpreted in . light of the potential impact to the immune system. In 420 vivo test systems lend themselves to a pathology evaluation, but background information in these systems is often limited. Use of a standard mouse strain to evaluate changes in host response to infectious agents could serve as an approach to assess immune status. However, the final application of a toxicologic pathology evaluation of the immune system is for hazard identification and risk assessment. Since toxicity to the immune system can be viewed as adverse health effects that result from exposure to the drug in both humans and animals, the toxicologic pathologist must establish the cross-species relevance of findings in animals to humans. A single-model system with historical data serves this purpose well.
The National Toxicology Program established criteria for immunotoxicity (2) . Alteration of T-cell-dependent antibody response linked with phenotypic characterization of lymphocyte subpopulations have been considered as important endpoints in classifying hazards (3, 4 ). Yet the interpretation of these identified hazards to risk assessment is not established. Herzyk et al propose that the identified hazards in a host susceptibility assay can be linked to host survival (i.e., risk). In making this link in a single model, the complexity of the immune system is reduced and assessment completed through a series of key measures. Welwyn, Herts AL6 9AR, United Kingdom
